Palisade Bio Advances IBD Drug into Phase 2 Trials with Strong Clinical Data
Event summary
- Palisade Bio reported positive Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease, showing sustained exposure and favorable safety profile.
- Phase 2 ulcerative colitis trial expected to commence in Q3 2026, with IND submission targeted for Q2 2026.
- Company had $132.6 million in cash as of March 31, 2026, sufficient to fund operations through 2028.
- Research and development expenses increased by $5.4 million YoY due to clinical trial and CMC expenses.
The big picture
Palisade Bio’s advancement of PALI-2108 into Phase 2 trials positions it as a key player in the inflammatory bowel disease (IBD) space. The company’s differentiated prodrug platform aims to improve pharmacology and tolerability, addressing a significant unmet need in chronic inflammatory and fibrotic diseases. The strong clinical data and robust financial position suggest potential for long-term value creation, though execution risks remain.
What we're watching
- Clinical Progress
- Whether PALI-2108 can replicate positive Phase 1b results in Phase 2 trials for ulcerative colitis and Crohn’s disease.
- Execution Risk
- The pace at which Palisade Bio can advance both ulcerative colitis and Crohn’s disease trials, given the staggered timelines.
- Financial Runway
- How the company’s $132.6 million cash position will support operations through key clinical readouts in 2027 and 2028.
Related topics